Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    The MAHA Trend in Groceries Will Backfire

    24. August 2025

    Many college students turn to ChatGPT for therapy. Is that OK?

    24. August 2025

    WHO declares Kenya free of deadly sleeping sickness after decades

    24. August 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»News»Artera Launches Real-World Registry to Track AI’s Impact in Cancer Care
    News

    Artera Launches Real-World Registry to Track AI’s Impact in Cancer Care

    HealthradarBy Healthradar19. Juni 2025Keine Kommentare2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Artera Launches Real-World Registry to Track AI’s Impact in Cancer Care
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Artera Launches Real-World Registry to Track AI’s Impact in Cancer Care

    What You Should Know: 

    – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the launch of its DIRECT-AI registry study. This new study will assess how the ArteraAI Prostate Test influences treatment decision-making between clinicians and patients with localized prostate cancer.

    – The study will also monitor participants to evaluate their long-term cancer outcomes, reinforcing Artera’s commitment to advancing personalized cancer treatment and identifying future opportunities for test optimization.

    Prostate Cancer Care Test

    The DIRECT-AI study centers on the award-winning ArteraAI Prostate Test, which holds a unique position in the field. It is the only test included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for localized prostate cancer that can both predict therapy benefit and prognosticate long-term outcomes.

    The study is structured into two distinct phases to capture both immediate and long-term insights:

    • Phase One: This initial phase will capture real-world data on how the ArteraAI Prostate Test informs clinical decision-making. Feedback will be collected directly from participating clinicians and their patients.
    • Phase Two: The second phase will involve long-term monitoring of health outcomes at key intervals of 2 and 5 years. The study will look at critical endpoints such as distant metastasis, survival rates, and treatment effectiveness. This research will help Artera understand the real-world impact of its test and identify areas for future improvement.

    How Patients and Clinics Can Participate

    The study is designed to be seamless and non-interventional, meaning it does not require additional procedures or tests for participants.

    • Patient Eligibility: Any patient receiving the commercial ArteraAI Prostate Test and whose ordering physician is associated with an enrolling clinic is eligible. Patients must have localized prostate cancer and must not have started or received treatment for their condition.
    • Clinic Participation: For clinics participating in the DIRECT-AI Registry, physicians can easily enroll all patients for whom they order an ArteraAI Prostate Test into the study.

    “Harnessing the power of AI, the ArteraAI Prostate Test marks a significant advancement in the personalized treatment of localized prostate cancer,” said Dr. Tim Showalter, Chief Medical Officer at Artera. “Through the DIRECT-AI registry, we are rigorously evaluating how this technology can enhance clinical decision-making and improve patient outcomes, providing clinicians and patients with the most accurate, tailored insights available.”



    Source link

    AIs Artera Artificial Intelligence cancer Care Impact Launches Oncology RealWorld Registry track
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleWork-Life Balance Matters More Than Pay for Many UK Doctors, Medscape Survey Reveals
    Next Article Altera Digital Health Makes Sunrise 25.1 Generally Available to Hospitals and Health Systems
    ekass777x
    Healthradar
    • Website

    Related Posts

    News

    Charlie Health Expands Virtual Behavioral Healthcare to Ages 8-64

    23. August 2025
    News

    Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

    22. August 2025
    News

    The robotic surgery market battle is heating up

    22. August 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202540 Views

    Linea Expands AI-Powered Heart Failure Care Solution

    6. August 202518 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202517 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20259 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202540 Views

    Linea Expands AI-Powered Heart Failure Care Solution

    6. August 202518 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.